

US BIODEFENSE INC  
Form NT 10-Q  
October 12, 2005

U.S. SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

(Check One):

Form 10-K

Form 20-F

Form 11-K

**Form 10-Q**  Form N-SAR

For Period Ended: August 31, 2005

Transition Report on Form 10-K

Transition Report on Form 20-F

Transition Report on Form 11-K

Transition Report on Form 10-Q

Transition Report on Form N-SAR

For the Transition Period Ended: N/A

Read attached Instruction sheet before preparing form. Please print or type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A

---

**PART 1 - Registrant Information**

---

Full name of Registrant: US BIODEFENSE, INC.

Former Name if applicable: PIEDMONT, INC.

Address of Principal Executive Office:

13674 E. Valley Blvd.

Street and Number

City of Industry, California 91746

City, State, and Zip Code

---

---

**PART II - Rules 12b-25 (b) and (c)**

---

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b - 25(b), the following should be completed. (Check box if appropriate)

<b>[X]</b>	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant's statement or other exhibit required by Rule 12b-25c has been attached if applicable.

---

**PART III - Narrative**

---

State below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof could not be filed within the prescribed period.

Management's Discussion and Analysis of Financial Condition and Results of Operation, as related to the registrant's financial information, and certain aspects of the financial information will not be completed in sufficient time to file the Quarterly Report on Form 10-QSB for the period ended August 31, 2005 by October 14, 2005.

---

**PART IV- Other Information**

---

Edgar Filing: US BIODEFENSE INC - Form NT 10-Q

(1) Name and telephone number of person to contact in regard to this notification:

David Chin  
(Name)

(626)  
(Area Code)

961-8039  
(Telephone Number)

(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

Yes [ ] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

[ ] Yes  No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

---

**US BIODEFENSE, INC.**

(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: October 11, 2005

By: /s/ David Chin

David Chin, President

Edgar Filing: US BIODEFENSE INC - Form NT 10-Q

**INSTRUCTION:** The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.